Breaking
•John Mayer Signs With Mercury Records•STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial•ULB polls: Andhra Pradesh SEC extends nomination window for Kadapa, Rajampet, Mydukur and Tirupati after SC order•Breaking down Blue Hawk basketball ahead of the 2026-27 basketball season - The Dickinson Press•Breaking: Mumford Fire reported in Placer County on Oct. 22 - Fresno Bee•Everything you need for Gameweek 8 of FPL with the latest tips and advice - Premier League•Virginia Democrat indicted on federal drug and money laundering charges•U.S. scaling back troops and diplomats at Middle East posts, sources say - NBC News•DAILY NEWS RECAP The Middle East is moving closer to another major escalation. The U.S. is shifting aircraft and personnel away from vulnerable Gulf bases, another carrier is moving toward the region, and Pakistan and Qatar are reportedly making a last-d - X•Europe’s rights court rejects bias claims over former Italian premier’s tax fraud conviction - Courthouse News•Who's to blame for Man United mess: Carrick, the players ... Ratcliffe? - ESPN•Discord now formats Markdown previews right•Chaka Khan to Receive Classic Soul Honor at 2026 Soul Train Awards•Sony Pictures TV Signs Content Creator Thea Von Engelbrechten to First-Look Deal, Launches Animated Microdrama ‘Hazelwood’ (EXCLUSIVE)•Visually impaired students of Andhra Loyola College trained in assistive technology•‘IFP’s priorities at the moment are built around preservation of our collections’•Dasara festivities: 18.29 lakh devotees visit Vijayawada Kanaka Durga temple•Breaking: Tadpole Fire reported in Placer County on Oct. 22 - Sacramento Bee•ElevateMeD Awards Three Medical Students Scholarships - The University of Arizona College of Medicine – Phoenix•West Virginia investigates environmental groups over 'deceptive' climate change advocacy - New Haven Register•John Mayer Signs With Mercury Records•STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial•ULB polls: Andhra Pradesh SEC extends nomination window for Kadapa, Rajampet, Mydukur and Tirupati after SC order•Breaking down Blue Hawk basketball ahead of the 2026-27 basketball season - The Dickinson Press•Breaking: Mumford Fire reported in Placer County on Oct. 22 - Fresno Bee•Everything you need for Gameweek 8 of FPL with the latest tips and advice - Premier League•Virginia Democrat indicted on federal drug and money laundering charges•U.S. scaling back troops and diplomats at Middle East posts, sources say - NBC News•DAILY NEWS RECAP The Middle East is moving closer to another major escalation. The U.S. is shifting aircraft and personnel away from vulnerable Gulf bases, another carrier is moving toward the region, and Pakistan and Qatar are reportedly making a last-d - X•Europe’s rights court rejects bias claims over former Italian premier’s tax fraud conviction - Courthouse News•Who's to blame for Man United mess: Carrick, the players ... Ratcliffe? - ESPN•Discord now formats Markdown previews right•Chaka Khan to Receive Classic Soul Honor at 2026 Soul Train Awards•Sony Pictures TV Signs Content Creator Thea Von Engelbrechten to First-Look Deal, Launches Animated Microdrama ‘Hazelwood’ (EXCLUSIVE)•Visually impaired students of Andhra Loyola College trained in assistive technology•‘IFP’s priorities at the moment are built around preservation of our collections’•Dasara festivities: 18.29 lakh devotees visit Vijayawada Kanaka Durga temple•Breaking: Tadpole Fire reported in Placer County on Oct. 22 - Sacramento Bee•ElevateMeD Awards Three Medical Students Scholarships - The University of Arizona College of Medicine – Phoenix•West Virginia investigates environmental groups over 'deceptive' climate change advocacy - New Haven Register
TheNewsPulse.pro
Home/clinical trials/diseases/drugs
clinical_trials

STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations

Confidence88·multiple reportsImportance90NP-EVT-20261022-D884F2F

AbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but missed market expectations.

Read the original at the primary source
STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations
Jonathan Wosen · 10/22/2026, 6:22:27 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse

Discussion

ChatsPulse · 0 threads

No discussion yet. Sign in and start the first thread —